Johnson & Johnson vaccine production problems at Emergent plant in Baltimore

The mixing of ingredients for coronavirus vaccines from Johnson & Johnson and AstraZeneca occurred at a plant operated by Emergent, which has not yet been certified by the Food and Drug Administration to produce the Johnson & Johnson vaccine.

Emergent is a contract manufacturer for bulk vaccine substance for drugmakers Johnson & Johnson and AstraZeneca. It also has federal agreements for the production of medicines to combat bioterrorism threats.

Emergent did not respond to requests for comment Wednesday.

None of the contaminated vaccine made it out of the plant, according to a federal official who was not authorized to discuss the matter. It had not reached the “fill-and-finish” stage of production, which involves final formulation and filling vials after bulk vaccine is shipped to a Catalent plant in Indiana.

“We are going to make sure that we understand what happened,” said a health official, who spoke on the condition of anonymity because he was not authorized to discuss the situation. “We have to work through and find out what is going on.”

Johnson & Johnson provided no details in a statement but said it was beefing up staff and oversight of vaccine manufacturing at the plant in Baltimore.

It has been shipping raw ingredients from Europe pending certification of the Emergent facility.

“Johnson & Johnson is providing additional experts in manufacturing, technical operations and quality to be on-site at Emergent to supervise, direct and support all manufacturing of the Johnson & Johnson coronavirus vaccine,” the company said in a statement.

The New York Times first reported the incident. It said that about 15 million doses were ruined and that federal officials had attributed it to human error.

Johnson & Johnson did not confirm the estimate of the volume that was ruined, but at Johnson & Johnson’s $10-a-dose price for the finished product, the value would be up to $150 million.

The federal official said the cross-contamination was caught on routine quality-control checks by Johnson & Johnson. “The issue is whether manufacturing processes at the plant are suboptimal,” said the official. “Nothing got out of the plant.”

The discovery was made a few days ago, setting off a flurry of meetings involving the FDA, Johnson & Johnson and the Biomedical Advanced Research and Development Authority in the Department of Health and Human Services.

Source link

Scroll to Top